Lukang Pharmaceutical receives approval for ceftizoxime sodium injection
Shandong Lukang Pharmaceutical Co., Ltd. has officially received the Drug Registration Certificates for its Ceftizoxime Sodium Injection (specifications: 0.5g, 1.0g) from the National Medical Products Administration, marking a significant step in the company's product development. Classified as a Category 4 chemical drug, the injection exhibits broad-spectrum antibacterial properties as a third-generation cephalosporin. According to Yaozhi.com, the market for Ceftizoxime Sodium Injection in China's urban public hospitals reached CNY 3.078 billion in 2024. As of the announcement date, Lukang Pharmaceutical has invested approximately CNY 2.9455 million in the research and development of this injection. The company cautions investors that sales are subject to policy and market factors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shandong Lukang Pharmaceutical publishes news
Free account required • Unsubscribe anytime